Biotechnology
Remote Pre-Approval Inspection Completed by EMA on WuXi Biologics' MFG4 Facility
WUXI, China, March 3, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that the European Medicines Agency (EMA) has completed a remote Pre-Approval Inspection (PAI) on its drug substance facility ...
2021-03-03 18:23
2638
Biotheus Announces the Closing of a New Round of Financing co-led by General Atlantic and IDG Capital
ZHUHAI, China, March 2, 2021 /PRNewswire/ -- Biotheus has announced the successful completion of a fourth round of financing, co-led by General Atlantic, a leading global growth equity investor, and IDG Capital, a global leading investment firm. Other new investors include Kunlun Capital, CPE, an...
2021-03-03 11:37
1830
CMAB Biopharma Congratulates Partner Innovent Biologics on FDA Clearance of IND Application of its COVID-19 Antibody Project
SUZHOU, China, March 2, 2021 /PRNewswire/ -- CMAB Biopharma (Suzhou) Inc ("CMAB") congratulates its partner Innovent Biologics, Inc ("Innovent") (1801.HK) on the U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for its antibody candidate which ta...
2021-03-03 11:12
1824
Seegene's Latest COVID-19 Test Can Simultaneously Target 4 Genes of SARS-CoV-2 and Recognize Multiple Virus Variants
* Seegene's new product filters COVID-19 and variants during primary PCR testing in 1 hr 55 minutes * Seegene's proprietary high multiplex technology enables detection of 10 different targets * S. Korean firm to research additional versions of variant diagnostic tests SEOUL, South Korea,...
2021-03-03 09:20
2092
AGC Biologics Announces the Expansion of Their Cell and Gene Therapy Facility in Milan, Italy
SEATTLE, March 3, 2021 /PRNewswire/ -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced plans for the expansion of their Cell and Gene Therapy Center of Excellence inMilan, to increase capacities and implement viral vector su...
2021-03-03 08:00
3760
Sunquest Lauded by Frost & Sullivan for Driving Efficiency and Compliance with Its Differentiated Molecular Laboratory Information Management System
Sunquest provides various interoperable products and services that work with each other to improve lab efficiency and results accuracy LONDON, March 2, 2021 /PRNewswire/ -- Based on its recent analysis of the North American laboratory information management systems (LIMS) market for molecular an...
2021-03-02 22:00
1665
Global Cord Blood Corporation Announces Receipt of Unsolicited Non-Binding Acquisition Proposal
HONG KONG, March 2, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that its board of directors (the "...
2021-03-02 20:00
11319
Merck and GPHL Collaborate on Business Innovation and Development in the Greater Bay Area
GUANGZHOU, China, March 2, 2021 /PRNewswire/ -- Merck, a leading science and technology company, today signed a Memorandum of Understanding (MOU) to begin strategic collaboration with Guangzhou Pharmaceutical Holdings Limited (GPHL), China's leading pharmaceutical company. The collaboration aim...
2021-03-02 18:12
3964
Cipla receives final approval for generic version of GlaxoSmithKline's IMITREX® (Sumatriptan Nasal Spray, 20 mg)
MUMBAI, India, March 2, 2021 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (hereinafter referred to as "Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray, 20 mg from the United States Food and Drug...
2021-03-02 16:01
5444
CMAB Biopharma Congratulates QureBio on FDA Clearance of IND Application for Claudin18.2/PD-L1 Bispecific Antibody
SUZHOU, China, March 2, 2021 /PRNewswire/ -- Recently, CMAB Biopharma (Suzhou) Inc's ("CMAB") partner QureBio Ltd ("QureBio") has announced its innovative drug Q-1802 received United States Food and Drug Administration (FDA) clearance for an Investigational New Drug (IND) application. This applic...
2021-03-02 13:43
1908
Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB
SYDNEY, March 2, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical AB (STO: OASM), an innovation-focuse...
2021-03-02 07:00
5006
INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18
Trial achieved primary and secondary efficacy endpoints among all evaluable subjects in the Phase 3 multi-center, randomized, double-blind, placebo-controlled trial VGX-3100 is the first DNA medicine to achieve efficacy endpoints in a Phase 3 clinical trial INOVIO also continues to partner with...
2021-03-02 05:05
5638
China Biologic Announces Shareholders' Approval of Merger Agreement
BEIJING, March 1, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that, at an extraordinary general meeting (the "EGM") held today, the Company...
2021-03-01 21:00
10752
Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development
SUZHOU, China, March 1, 2021 /PRNewswire/ -- Suzhou Medilink Therapeutics Ltd. (Medilink), a global biotech company focusing on next-generation antibody-drug conjugate Research & development, announced the closing of a$50 million series A financing, to accelerate its innovative pipeline developme...
2021-03-01 19:50
5203
CARsgen Therapeutics Receives Orphan Medicinal Product Designation from the European Medicines Agency for CT041 CLDN18.2 CAR T Cells for the Treatment of Gastric Cancers
SHANGHAI, March 1, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited, a clinical-stage biopharmaceutical company, today announced that the European Commission (EC) has granted orphan designation for CT041, CARsgen's first-in-class Claudin 18.2 (CLDN18.2) targeted CAR-T product candidate ...
2021-03-01 19:00
4129
Merck Builds on Leadership in Head and Neck Cancer Through Worldwide Licensing Agreement with Debiopharm for Pivotal-Stage Xevinapant
- Xevinapant is the first Inhibitor of Apoptosis Proteins antagonist with FDA Breakthrough Therapy Designation for previously untreated locally advanced squamous cell carcinoma of the head and neck, in combination with current standard of care - A Phase II trial reported that xevinapant plus che...
2021-03-01 18:48
2834
Avalon SteriTech and SoftBank Robotics Group Launch New Joint Venture to Develop and Promote Innovative Public Healthcare and Hygiene Solutions
HONG KONG, March 1, 2021 /PRNewswire/ -- Avalon SteriTech Limited ("Avalon") and SoftBank Robotics Group ("SBRG") today announced a joint venture focusing on the development of innovative products and technologies that strive to empower and benefit public health and well-being. The joint venture ...
2021-03-01 13:00
2148
Sciwind's Investigational New Drug Approved for NASH Trial
HANGZHOU, China, March 1, 2021 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd., (Sciwind), a clinical-stage, fast-growing biotech focusing on research and development of innovative biologics, today announced that XW003, a potential candidate for the treatment of non-alcoholic steatohepatit...
2021-03-01 09:00
3399
Innovent Announces First Patient Outside China Dosed in the Phase 1 Clinical Trial of Anti-CD47/PD-L1 Bispecific Antibody
SAN FRANCISCO and SUZHOU, China, March 1, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major di...
2021-03-01 08:23
7496
Antengene (6996.HK) Selected as a Constituent Stock of Nine Benchmark and Thematic Indexes Including the Hang Seng Composite Index
SHANGHAI and HONG KONG, Feb. 28, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncol...
2021-03-01 08:00
6275
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 321 media titles]
2026-02-16 10:00
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 317 media titles]
2026-02-19 14:30
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 277 media titles]
2026-02-17 19:12
Tower Capital Asia announces majority investment in V-Key - a leader in digital identity and mobile application security
[Picked up by 265 media titles]
2026-02-13 01:52
Appier Delivers Record Results Driven by Agentic AI Innovation
[Picked up by 263 media titles]
2026-02-13 17:03Most Read
eufy Raises the Bar for Home Cleaning with Omni C28, Delivering One-Pass-Clean Performance with HydroJet™ Self-Clean Roller Mop
2026-02-14 10:00
7806
Cboe Launches Nearly 24-Hour Trading in Russell 2000 Index Options
2026-02-13 07:30
6882
Appier Delivers Record Results Driven by Agentic AI Innovation
2026-02-13 17:03
6522